Medsolve Dynamics

Acceptance proves the machine is what was bought. It says nothing about the volume the purchase was approved on. Yoel Bakas of Medsolve Dynamics, twenty years on the vendor side of these agreements, on which assumptions a capital purchase puts somebody on the hook for and which ones belong to the program alone.   medsolvedynamics.com · team@medsolvedynamics.com

Before asking for another treatment machine, establish what limits the ones already in service. Yoel Bakas of Medsolve Dynamics explains why a capital review needs staffed hours and treatment mix beside the activity figures, and how those conditions affect a comparison with the vendor's proposal.   medsolvedynamics.com · team@medsolvedynamics.com

Twenty years on the vendor side, and an honest answer about which machine to buy would still have been his machine. Yoel Bakas on where a vendor's physicist sits on that one question, and only that one, and what to write down under each physics arrangement before the next capital decision. Full issue: oncologyoperator.com . Yoel Bakas ran national accounts at GE HealthCare, strategic operations at...

One flat service rate on a one-year-old linear accelerator and a twenty-year-old one means the LINAC service contract price is not built from parts, labor, travel or downtime history. Yoel Bakas on the number to check before a radiation oncology service agreement renewal or a service contract negotiation. Clip from the AMAC Summer Seminar 2026. Yoel Bakas ran national accounts at GE HealthCare, st...

Yoel Bakas on why a competing bid earns its keep even when everyone knows which vendor wins, and what one question did for a vault budget. From Yoel Bakas's AMAC Summer Seminar 2026 session; this cut is an episode of the Medsolve Dynamics podcast. Yoel Bakas ran national accounts at GE HealthCare, strategic operations at ViewRay and global sales at Mevion. He founded Medsolve Dynamics to work the...

Every hospital-based cancer program pays its own institution for space, lab and IT, and almost none can show how the figure was built. Yoel Bakas on why the largest number in a capital file is often the one nobody negotiates. From Medsolve Dynamics. medsolvedynamics.com | team@medsolvedynamics.com

Every service agreement has one clause that grows on its own, and it is almost never the clause that gets negotiated. Yoel Bakas on what a five percent annual step actually costs across a five year term, why the arithmetic surprises people who have signed dozens of these, and where the money goes when nobody owns the renewal date. Recorded at the AMAC Summer Seminar 2026. From Medsolve Dynamics. m...

The radiopharmaceutical supply chain consolidated on paper on August 3, 2026, when Curium and Lantheus signed a definitive merger agreement. Yoel Bakas on why the period between signing and closing — an outside date of May 2, 2027, with extensions capped at November 30 — is the only window in which a supplier has a structural reason to give you terms, and what to ask for while it is open. From Med...

A radiation oncology capital price that has not moved in twenty years. Onboard imaging, arc delivery, the next iteration of arc delivery, a couch upgrade — all half a million dollars. The same couch is $250,000 on the older platform and half a million on the new one. Yoel Bakas spent two decades on the vendor side handing programs that number, and explains what it actually is: an anchor set to sha...

Yoel Bakas, computer science and an MBA in artificial intelligence, twenty years configuring and pricing this class of technology from the vendor side, on the two questions radiation oncology and theranostics programs should ask before buying AI response-monitoring or workflow software: does it have a billing pathway (or is it an operating expense with no code to bill against), and who owns the ou...

The CY 2027 OPPS proposed rule puts the 340B drug spread underneath hospital theranostics programs on the table. Two drugs carry the category, Pluvicto and Lutathera, and for many programs the spread is what made the line lucrative. This episode covers the discipline: nobody tears up a program on a proposed rule, and nobody signs capital before checking whether the plan still works if the rule sti...

Parts lead time and field-engineer coverage, not the uptime percentage in your contract, decide how long a LINAC is actually down. A vendor-side look at how service coverage models are built around the vendor's cost, not your schedule, and what that costs your throughput and margin. LINAC downtime, service coverage, parts logistics, field engineer, uptime SLA, throughput, time toxicity. medsolvedy...

A radiation oncology service contract that quotes the same rate on a one-year-old LINAC and a twenty-year-old one was never priced on the cost to serve the machine. It was priced to anchor you. How to make a LINAC service price prove it is tied to cost. LINAC service contract, service pricing, capital negotiation, vendor negotiation, AMAC, purchasing framework. medsolvedynamics.com team@medsolvedy...

Your first capital negotiation is against someone who runs forty a year. This explains where the vendor puts the leverage and how a new administrator levels the field. New administrator, capital negotiation, vendor meeting, supervision coverage, radiation oncology.

A percentage off a list price the vendor set themselves tells you very little. This explains why the value package matters more than the discount in a LINAC capital negotiation, and what a program should structure for instead. Capital strategy, vendor quote, service contract, radiation oncology. medsolvedynamics.com team@medsolvedynamics.com

Vendor AI demos show real efficiency that never reaches the staffing model. The workflow redesign and oversight cost behind AI value in radiation oncology. medsolvedynamics.com | team@medsolvedynamics.com #AIinHealthcare #RadiationOncology #WorkflowFit #OncologyOperations

Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply. medsolvedynamics.com | team@medsolvedynamics.com #Theranostics #RadioligandTherapy #IsotopeSupply #OncologyOperations

AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo. medsolvedynamics.com | team@medsolvedynamics.com   #Radiation...

In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor...

A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affe...

Most rad onc programs walk into a service contract renewal with no independent numbers on the table. The vendor brings their performance data. The program nods. The renewal runs the vendor's direction. The gap is not in the contract language. It is in the measurement asymmetry. Five metrics the vendor tracks and the program rarely does. Uptime delivered against contracted spec. Response time again...

At ESTRO 2026, United Imaging showed a CE-marked uRT-linac 506c on the show floor. Diagnostic-CT integrated with a linear accelerator on a single platform. Online adaptive radiotherapy positioned without an MR-linac, without a third-party planning system, and without RaySearch. Reported as CE marked in Europe. Not yet in the US market. Capital decisions in flight in the US in 2026 are not changing...

Most rad onc programs sitting on soft Q2 numbers are looking outside the building for offsetting revenue. The infrastructure for radioligand therapy is already inside the building, and a Jefferson-authored paper accepted by Practical Radiation Oncology in May 2026 puts the 340B-eligible hospital gross margin at roughly $101,000 per Pluvicto patient over a full course. The same paper names why prog...

From 20 years on the vendor side of oncology software sales, the one question that exposes the AI price premium baked into software renewal quotes in 2026. Treatment planning systems, contouring software, registry products, SaaS modules. The AI features were priced higher than the same software would have priced two years ago. Get the unbundled price. medsolvedynamics.com | team@medsolvedynamics.c...

A vendor-side story Yoel Bakas has watched play out dozens of times in radiation oncology. A software demo runs without anyone asking what is actually broken in the customer's workflow. The tool gets relabeled AI-enabled a year later. Until the customer understands what is broken, it does not matter what the tool is. AI in radiation oncology, workflow design, vendor evaluation, capital decision. m...